Overview Dividends

(THC) Tenet Healthcare - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US88033G4073

Hospital Care, Ambulatory Surgery, Urgent Care, Imaging Centers

THC EPS (Earnings per Share)

EPS (Earnings per Share) of THC over the last years for every Quarter: "2020-09": 0.64, "2020-12": 4.72, "2021-03": 1.3, "2021-06": 1.59, "2021-09": 1.99, "2021-12": 2.7, "2022-03": 1.93, "2022-06": 1.5, "2022-09": 1.44, "2022-12": 1.96, "2023-03": 1.42, "2023-06": 1.44, "2023-09": 1.44, "2023-12": 2.68, "2024-03": 3.22, "2024-06": 2.31, "2024-09": 2.93, "2024-12": 3.44, "2025-03": 4.36, "2025-06": 4.02, "2025-09": 3.7,
EPS Growth (3Y CAGR): 25.99%
EPS Trend (3Y Correlation): 86.7%

THC Revenue

Revenue of THC over the last years for every Quarter: 2020-09: 4557, 2020-12: 4915, 2021-03: 4781, 2021-06: 4954, 2021-09: 4894, 2021-12: 4856, 2022-03: 4745, 2022-06: 4638, 2022-09: 4801, 2022-12: 4990, 2023-03: 5021, 2023-06: 5082, 2023-09: 5066, 2023-12: 5379, 2024-03: 5368, 2024-06: 5103, 2024-09: 5122, 2024-12: 5072, 2025-03: 5223, 2025-06: 5271, 2025-09: 5289,
Revenue Growth (3Y CAGR): 2.14%
Revenue Trend (3Y Correlation): 52.4%

Description: THC Tenet Healthcare October 16, 2025

Tenet Healthcare Corp. (NYSE: THC) is a diversified U.S. health-services operator that runs two primary segments-Hospital Operations & Services and Ambulatory Care-covering acute-care hospitals, specialty surgery centers, urgent-care and micro-hospital facilities, plus a broad portfolio of clinical services ranging from cardiothoracic surgery to tele-medicine.

Key operating metrics (FY 2023) show revenue of roughly $15.3 billion, an adjusted EBITDA margin near 8 % and an average hospital occupancy rate of about 71 %, reflecting modest demand growth amid a tightening labor market. The business is especially sensitive to Medicare-DRG reimbursement trends, regional labor-cost inflation, and the broader industry shift toward outpatient and tele-health delivery models, which together drive both volume and margin dynamics.

For a deeper, data-driven look at THC’s valuation multiples and peer benchmarks, you may find ValueRay’s analytical tools worth exploring.

THC Stock Overview

Market Cap in USD 18,478m
Sub-Industry Health Care Facilities
IPO / Inception 1982-01-04

THC Stock Ratings

Growth Rating 86.4%
Fundamental 79.2%
Dividend Rating 5.93%
Return 12m vs S&P 500 9.72%
Analyst Rating 4.32 of 5

THC Dividends

Currently no dividends paid

THC Growth Ratios

Growth Correlation 3m 91.6%
Growth Correlation 12m 74.1%
Growth Correlation 5y 78.6%
CAGR 5y 72.33%
CAGR/Max DD 3y (Calmar Ratio) 1.96
CAGR/Mean DD 3y (Pain Ratio) 8.78
Sharpe Ratio 12m 1.66
Alpha 0.64
Beta 1.523
Volatility 40.14%
Current Volume 1127.5k
Average Volume 20d 991.2k
Stop Loss 200.2 (-3%)
Signal 0.22

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (1.35b TTM) > 0 and > 6% of Revenue (6% = 1.25b TTM)
FCFTA 0.05 (>2.0%) and ΔFCFTA -3.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 15.58% (prev 15.36%; Δ 0.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.08 (>3.0%) and CFO 2.48b > Net Income 1.35b (YES >=105%, WARN >=100%)
Net Debt (-2.89b) to EBITDA (4.17b) ratio: -0.69 <= 3.0 (WARN <= 3.5)
Current Ratio 1.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (88.6m) change vs 12m ago -8.32% (target <= -2.0% for YES)
Gross Margin 55.93% (prev 39.55%; Δ 16.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 70.95% (prev 71.40%; Δ -0.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 4.09 (EBITDA TTM 4.17b / Interest Expense TTM 819.0m) >= 6 (WARN >= 3)

Altman Z'' 2.13

(A) 0.11 = (Total Current Assets 7.81b - Total Current Liabilities 4.56b) / Total Assets 29.42b
(B) 0.14 = Retained Earnings (Balance) 4.04b / Total Assets 29.42b
(C) 0.11 = EBIT TTM 3.35b / Avg Total Assets 29.39b
(D) 0.19 = Book Value of Equity 3.88b / Total Liabilities 20.72b
Total Rating: 2.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 79.18

1. Piotroski 6.50pt = 1.50
2. FCF Yield 9.64% = 4.82
3. FCF Margin 7.20% = 1.80
4. Debt/Equity 0.02 = 2.50
5. Debt/Ebitda -0.69 = 2.50
6. ROIC - WACC (= 4.24)% = 5.30
7. RoE 33.61% = 2.50
8. Rev. Trend 52.35% = 3.93
9. EPS Trend 86.74% = 4.34

What is the price of THC shares?

As of November 01, 2025, the stock is trading at USD 206.49 with a total of 1,127,483 shares traded.
Over the past week, the price has changed by -1.85%, over one month by +1.70%, over three months by +28.03% and over the past year by +33.20%.

Is Tenet Healthcare a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Tenet Healthcare (NYSE:THC) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 79.18 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of THC is around 270.72 USD . This means that THC is currently undervalued and has a potential upside of +31.11% (Margin of Safety).

Is THC a buy, sell or hold?

Tenet Healthcare has received a consensus analysts rating of 4.32. Therefore, it is recommended to buy THC.
  • Strong Buy: 12
  • Buy: 5
  • Hold: 5
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the THC price?

Issuer Target Up/Down from current
Wallstreet Target Price 227.4 10.1%
Analysts Target Price 227.4 10.1%
ValueRay Target Price 310.2 50.2%

THC Fundamental Data Overview October 30, 2025

Market Cap USD = 18.48b (18.48b USD * 1.0 USD.USD)
P/E Trailing = 14.2175
P/E Forward = 13.1406
P/S = 0.8864
P/B = 4.793
P/EG = 0.8537
Beta = 1.523
Revenue TTM = 20.86b USD
EBIT TTM = 3.35b USD
EBITDA TTM = 4.17b USD
Long Term Debt = 13.08b USD (from longTermDebt, last fiscal year)
Short Term Debt = 85.0m USD (from shortTermDebt, last quarter)
Debt = 85.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.89b USD (from netDebt column, last quarter)
Enterprise Value = 15.59b USD (18.48b + Debt 85.0m - CCE 2.98b)
Interest Coverage Ratio = 4.09 (Ebit TTM 3.35b / Interest Expense TTM 819.0m)
FCF Yield = 9.64% (FCF TTM 1.50b / Enterprise Value 15.59b)
FCF Margin = 7.20% (FCF TTM 1.50b / Revenue TTM 20.86b)
Net Margin = 6.49% (Net Income TTM 1.35b / Revenue TTM 20.86b)
Gross Margin = 55.93% ((Revenue TTM 20.86b - Cost of Revenue TTM 9.19b) / Revenue TTM)
Gross Margin QoQ = 58.33% (prev 82.32%)
Tobins Q-Ratio = 0.53 (Enterprise Value 15.59b / Total Assets 29.42b)
Interest Expense / Debt = 242.4% (Interest Expense 206.0m / Debt 85.0m)
Taxrate = 18.68% (133.0m / 712.0m)
NOPAT = 2.72b (EBIT 3.35b * (1 - 18.68%))
Current Ratio = 1.71 (Total Current Assets 7.81b / Total Current Liabilities 4.56b)
Debt / Equity = 0.02 (Debt 85.0m / totalStockholderEquity, last quarter 4.01b)
Debt / EBITDA = -0.69 (Net Debt -2.89b / EBITDA 4.17b)
Debt / FCF = -1.92 (Net Debt -2.89b / FCF TTM 1.50b)
Total Stockholder Equity = 4.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.60% (Net Income 1.35b / Total Assets 29.42b)
RoE = 33.61% (Net Income TTM 1.35b / Total Stockholder Equity 4.03b)
RoCE = 19.56% (EBIT 3.35b / Capital Employed (Equity 4.03b + L.T.Debt 13.08b))
RoIC = 15.81% (NOPAT 2.72b / Invested Capital 17.21b)
WACC = 11.58% (E(18.48b)/V(18.56b) * Re(11.63%) + (debt cost/tax rate unavailable))
Discount Rate = 11.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -7.77%
[DCF Debug] Terminal Value 70.67% ; FCFE base≈1.86b ; Y1≈2.29b ; Y5≈3.91b
Fair Price DCF = 431.3 (DCF Value 38.11b / Shares Outstanding 88.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 86.74 | EPS CAGR: 25.99% | SUE: 0.75 | # QB: 0
Revenue Correlation: 52.35 | Revenue CAGR: 2.14% | SUE: 0.24 | # QB: 0

Additional Sources for THC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle